Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?
作者信息
Gravara Luigi Della, Battiloro Ciro, Cantile Rosa, Letizia Antonietta, Vitiello Fabiana, Montesarchio Vincenzo, Rocco Danilo
机构信息
Department of Experimental Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy.
Division of Pulmonary Oncology, AORN dei Colli Monaldi, Naples, Italy.
出版信息
Lung Cancer Manag. 2020 Feb 12;9(1):LMT22. doi: 10.2217/lmt-2019-0018.
Abstract
摘要
相似文献
1
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?非小细胞肺癌一线治疗中的化疗和/或免疫检查点抑制剂：最佳治疗方法是什么？
Lung Cancer Manag. 2020 Feb 12;9(1):LMT22. doi: 10.2217/lmt-2019-0018.
2
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
3
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?程序性细胞死亡配体-1（PD-L1）作为非小细胞肺癌（NSCLC）治疗的生物标志物——我们找错方向了吗？
Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.
4
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.选择最佳一线治疗方案：无可操作致癌驱动因素的非小细胞肺癌
Lung Cancer Manag. 2020 Jul 24;9(3):LMT36. doi: 10.2217/lmt-2020-0003.
5
Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.免疫疗法彻底改变了非小细胞肺癌的治疗：结果、前景与新挑战。
Eur J Cancer. 2017 Jun;78:16-23. doi: 10.1016/j.ejca.2016.12.041. Epub 2017 Apr 11.
6
Double immune checkpoint blockade in advanced NSCLC.晚期 NSCLC 的双重免疫检查点阻断。
Crit Rev Oncol Hematol. 2020 Aug;152:102980. doi: 10.1016/j.critrevonc.2020.102980. Epub 2020 May 19.
7
[Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies].[检查点抑制剂在食管和胃肿瘤治疗中的现状——研究综述]
Klin Onkol. 2017 Winter;31(1):35-39. doi: 10.14735/amko201835.
8
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies.帕博利珠单抗一线治疗晚期非小细胞肺癌的综述：聚焦于KEYNOTE研究
Cancer Manag Res. 2020 Jul 28;12:6493-6509. doi: 10.2147/CMAR.S257188. eCollection 2020.
9
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
10
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
引用本文的文献
1
Targeting multiple hallmarks of mammalian aging with combinations of interventions.用干预组合靶向哺乳动物衰老的多个标志。
Aging (Albany NY). 2024 Aug 18;16(16):12073-12100. doi: 10.18632/aging.206078.
2
Immune checkpoint inhibitors combined with paclitaxel-based chemotherapy versus chemotherapy alone as first-line treatment in HER2-negative advanced gastric cancer: result of a multicenter retrospective study.免疫检查点抑制剂联合基于紫杉醇的化疗与单纯化疗作为HER2阴性晚期胃癌一线治疗的多中心回顾性研究结果
J Gastrointest Oncol. 2024 Apr 30;15(2):585-596. doi: 10.21037/jgo-23-814. Epub 2024 Apr 28.
3
The emerging nanomedicine-based technology for non-small cell lung cancer immunotherapy: how far are we from an effective treatment.新兴的基于纳米医学的非小细胞肺癌免疫治疗技术：我们距离有效治疗还有多远。
Front Oncol. 2023 Apr 27;13:1153319. doi: 10.3389/fonc.2023.1153319. eCollection 2023.
4
Editorial: Combining chemo/radio therapy and immunotherapy for cancers-perfect mix of old and new.社论：癌症的化疗/放疗与免疫疗法联合——新旧疗法的完美结合
Front Immunol. 2023 Jan 12;13:1129623. doi: 10.3389/fimmu.2022.1129623. eCollection 2022.
5
A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.关于免疫检查点抑制剂及其联合疗法在肝细胞癌中的应用的全面综述：最新综述
Cancer Cell Int. 2022 Aug 23;22(1):269. doi: 10.1186/s12935-022-02682-z.
6
PD-L1 testing and clinical management of newly diagnosed metastatic non-small cell lung cancer in Spain: MOREL study.西班牙新诊断转移性非小细胞肺癌的PD-L1检测与临床管理：MOREL研究
Lung Cancer Manag. 2021 Nov 26;10(4):LMT53. doi: 10.2217/lmt-2021-0008. eCollection 2021 Dec.
7
The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives.数学模型在免疫肿瘤学中的作用：挑战与未来展望。
Pharmaceutics. 2021 Jul 2;13(7):1016. doi: 10.3390/pharmaceutics13071016.
8
The Position of EGF Deprivation in the Management of Advanced Non-Small Cell Lung Cancer.表皮生长因子剥夺在晚期非小细胞肺癌治疗中的地位
Front Oncol. 2021 Jun 15;11:639745. doi: 10.3389/fonc.2021.639745. eCollection 2021.
9
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment.骨髓来源细胞在化疗处理的肿瘤微环境中的双重作用
J Clin Med. 2020 Dec 2;9(12):3912. doi: 10.3390/jcm9123912.
10
Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy.非小细胞肺癌中的纳米医学：从传统治疗到免疫疗法
Cancers (Basel). 2020 Jun 18;12(6):1609. doi: 10.3390/cancers12061609.
本文引用的文献
1
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.一线帕博利珠单抗治疗 PD-L1 表达非常高的非小细胞肺癌患者的结局。
Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288.
2
The role of combination chemo-immunotherapy in advanced non-small cell lung cancer.联合化疗免疫治疗在晚期非小细胞肺癌中的作用。
Expert Rev Anticancer Ther. 2019 Jul;19(7):561-568. doi: 10.1080/14737140.2019.1631800. Epub 2019 Jun 25.
3
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
4
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.对于 PD-L1 高表达的晚期非小细胞肺癌患者的一线治疗：帕博利珠单抗或帕博利珠单抗联合化疗。
J Immunother Cancer. 2019 May 3;7(1):120. doi: 10.1186/s40425-019-0600-6.
5
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.阿替利珠单抗联合贝伐珠单抗和化疗治疗非小细胞肺癌（IMpower150）：一项随机、开放标签的 3 期临床试验中具有 EGFR 突变或基线肝转移患者的关键亚组分析。
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
6
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
7
Immuno-Oncology: Emerging Targets and Combination Therapies.免疫肿瘤学：新兴靶点与联合疗法
Front Oncol. 2018 Aug 23;8:315. doi: 10.3389/fonc.2018.00315. eCollection 2018.
8
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
9
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
Zotero 插件